Tag Archives: Difei Yang

Nektar Therapeutics Gets a Buy Rating from Mizuho Securities

In a report released today, Difei Yang from Mizuho Securities assigned a Buy rating to Nektar Therapeutics (NASDAQ: NKTR), with a price target of $89. The company’s shares closed yesterday at $75.66. Yang said: “We expect both Nektar and BMY

Concert Pharma Receives a Hold from Mizuho Securities

In a report released today, Difei Yang from Mizuho Securities assigned a Hold rating to Concert Pharma (NASDAQ: CNCE), with a price target of $23. The company’s shares closed yesterday at $19.96. According to TipRanks.com, Yang is a 5-star analyst

Mizuho Securities Releases a Buy Rating on Akebia Therapeutics

Mizuho Securities analyst Difei Yang assigned a Buy rating to Akebia Therapeutics (NASDAQ: AKBA) today and set a price target of $24. The company’s shares closed yesterday at $14.45. Yang noted: “We had a chance to catch up with CEO

Mizuho Securities Initiates a Buy Rating on Spark Therapeutics

In a report released today, Difei Yang from Mizuho Securities initiated coverage with a Buy rating on Spark Therapeutics (NASDAQ: ONCE) and a price target of $79. The company’s shares opened today at $52.63. Yang noted: “We see strong potential

Mizuho Securities Issues a Buy Rating on AveXis Inc

In a report released today, Difei Yang from Mizuho Securities assigned a Buy rating to AveXis Inc (NASDAQ: AVXS), with a price target of $147. The company’s shares opened today at $110.38. Yang observed: “We expect a pre-BLA meeting in

RegenXBio Initiated with a Hold at Mizuho Securities

In a report released today, Difei Yang from Mizuho Securities initiated coverage with a Hold rating on RegenXBio (NASDAQ: RGNX) and a price target of $28. The company’s shares opened today at $26.10. According to TipRanks.com, Yang is a 5-star